Insulin-Sparing Effects of Oral Semaglutide: an Analysis of PIONEER 8

The PIONEER 8 (NCT03021187) trial demonstrated significant glucose-lowering efficacy of oral semaglutide vs placebo in patients with type 2 diabetes (T2D) inadequately controlled with insulin. Additionally, oral semaglutide (7/14 mg daily) was associated with lower total daily insulin dose at treatment end (week 52) relative to baseline, vs placebo, suggesting an insulin-sparing effect. This post-hoc analysis characterized the transition of adding a glucagon-like peptide-1 receptor agonist to insulin and quantified reductions in total insulin dose seen when adding oral semaglutide.